CIDP01 baseline characteristics
| Characteristic | Placebo (n=17) | Rozanolixizumab (n=17) |
| Age (years), median (range) | 56.0 (38–66) | 58.0 (23–77) |
| Male, n (%) | 9 (53) | 9 (53) |
| Weight (kg), median (range) | 93.80 (51.2–117.1) | 85.00 (53.5–140.8) |
| Race, n (%) | ||
| Asian | 1 (6) | 0 |
| Black | 1 (6) | 1 (6) |
| White | 11 (65) | 15 (88) |
| Other/mixed | 4 (24) | 1 (6) |
| Ethnicity, n (%) | ||
| Hispanic or Latino | 1 (6) | 1 (6) |
| Not Hispanic or Latino | 13 (76) | 16 (94) |
| Missing | 3 (18) | 0 |
| Regions, n (%) | ||
| America | 5 (29) | 8 (47) |
| Europe | 12 (71) | 9 (53) |
| Duration of disease (years), median (range) | 5.79 (1.8–22.9) | 4.84 (0.9–49.0) |
| Disease severity at baseline, mean (SD) | ||
| iRODS centile metric score | 61.6 (17.9) | 58.6 (20.4) |
| Adjusted INCAT disability score | 2.8 (1.7) | 3.6 (1.8) |
| Clinician-assessed grip strength, maximum score | 77.35 (24.66) | 68.24 (32.48) |
| Patient-assessed grip strength, maximum score | 75.0 (26.9) | 76.0 (34.0) |
| CIDP medication at baseline, n (%) | ||
| Corticosteroids | 3 (18) | 3 (18) |
| Other immunosuppressants | 1 (6) | 2 (12) |
| Previous immunoglobulin treatment, n (%) | 17 (100) | 17 (100) |
| Subcutaneous | 3 (18) | 1 (6) |
| Intravenous | 14 (82) | 16 (94) |
| Previous immunoglobulin cycle type, n (%) | ||
| ≤1 week | 3 (18) | 2 (12) |
| 2 to <4 weeks | 5 (29) | 7 (4) |
| 4 to <6 weeks | 5 (29) | 8 (47) |
| ≥6 weeks | 4 (24) | 0 |
| CIDP phenotype, n (%) | ||
| Typical CIDP (definite/probable) | 16 (94) (13 (76)/3 (18)) | 16 (94) (15 (88)/1 (6))* |
| Atypical CIDP (definite/probable) | 1 (6) (1 (6)/0) | 1 (6) (1 (6)/0) |
*Two patients had anti-MAG antibodies (confirmed after inclusion), of whom only one had IgM paraproteinaemia at study entry.
CIDP, chronic inflammatory demyelinating polyradiculoneuropathy; INCAT, Inflammatory Neuropathy Cause and Treatment; iRODS, inflammatory Rasch-built Overall Disability Scale; MAG, myelin-associated glycoprotein.